<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.biopharminternational.com/view/mabxience-oncoprecision-onc001-adc-manufacturing-investment-agreement</loc>
      <lastmod>2026-11-18T15:22:52.745Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:22:52.745Z</news:publication_date>
        <news:title><![CDATA[mAbxience Backs OncoPrecision ADC With Investment, Manufacturing Deal]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/verismo-licenses-stanford-pack-it-in-vivo-kir-car-t-platform</loc>
      <lastmod>2026-11-18T14:33:44Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:33:44Z</news:publication_date>
        <news:title><![CDATA[Verismo Licenses Stanford PACK-IT Tech for In Vivo KIR-CAR T Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/visara-doses-first-patient-in-phase-2b-trial-pitting-bispecific-vis-101-against-aflibercept-in-wet-amd</loc>
      <lastmod>2026-11-18T14:01:14.525Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:01:14.525Z</news:publication_date>
        <news:title><![CDATA[Visara Doses First Patient in Phase 2b Trial Pitting Bispecific VIS-101 Against Aflibercept in Wet AMD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/biocon-s-pebrilzo-becomes-first-breast-cancer-treatment-biosimilar-approved-under-ema-s-tailored-clinical-approach</loc>
      <lastmod>2026-11-18T13:19:22.946Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:19:22.946Z</news:publication_date>
        <news:title><![CDATA[Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-cosentyx-approved-in-polymyalgia-rheumatica-a-phase-3-survival-win-for-an-aml-vaccine-and-173-million-for-in-vivo-bone-marrow-editing</loc>
      <lastmod>2026-11-17T21:52:14.074Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:52:07.342Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/marrow-therapeutics-173-million-series-a-b-bone-marrow-genetic-medicines</loc>
      <lastmod>2026-11-17T17:34:25.175Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:34:25.175Z</news:publication_date>
        <news:title><![CDATA[Marrow Therapeutics Raises $173 Million for In Vivo Blood Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/small-molecule-agility-informs-biologics-manufacturing-merck</loc>
      <lastmod>2026-11-17T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/commit-biologics-raises-60-million-to-take-complement-powered-immune-engager-com002-into-the-clinic</loc>
      <lastmod>2026-11-17T16:16:40.926Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:16:40.926Z</news:publication_date>
        <news:title><![CDATA[Commit Biologics Raises $60 Million to Take Complement-Powered Immune Engager COM002 Into the Clinic]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/next-generation-bioconjugate-design-calls-for-an-orthogonal-analytical-approach</loc>
      <lastmod>2026-11-17T14:48:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:48:00Z</news:publication_date>
        <news:title><![CDATA[Next-Generation Bioconjugate Design Calls for an Orthogonal Analytical Approach]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-approves-cosentyx-as-first-anti-il-17-biologic-for-polymyalgia-rheumatica</loc>
      <lastmod>2026-11-17T14:40:40.658Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:40:40.658Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Cosentyx as First Anti-IL-17 Biologic for Polymyalgia Rheumatica]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/sellas-cancer-vaccine-galinpepimut-s-overall-survival-phase-3-regal-aml</loc>
      <lastmod>2026-11-17T14:37:14Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:37:14Z</news:publication_date>
        <news:title><![CDATA[SELLAS Cancer Vaccine Improves Overall Survival in Phase 3 AML Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/one-injection-a-month-efimosfermin-takes-aim-at-cirrhosis-in-mash</loc>
      <lastmod>2026-11-17T14:11:51.042Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:11:51.042Z</news:publication_date>
        <news:title><![CDATA[One Injection a Month: Efimosfermin Takes Aim at Cirrhosis in MASH]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/examining-future-dna-enabled-therapies</loc>
      <lastmod>2026-11-17T11:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T11:00:00Z</news:publication_date>
        <news:title><![CDATA[Examining the Future of DNA-Enabled Therapies]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-hidden-cost-of-clinical-supply-unlocking-study-cash-flow-and-flexibility</loc>
      <lastmod>2026-11-17T05:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T05:00:00Z</news:publication_date>
        <news:title><![CDATA[The Hidden Cost of Clinical Supply: Unlocking Study Cash Flow and Flexibility]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/fda-s-rare-disease-framework-aims-for-consistency-across-review-divisions-says-former-fda-reviewer-paz-vellanki</loc>
      <lastmod>2026-11-16T19:17:44.582Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T19:17:44.582Z</news:publication_date>
        <news:title><![CDATA[FDA's Rare Disease Framework Aims for Consistency Across Review Divisions, Says Former FDA Reviewer Paz Vellanki]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-fda-rejects-ivonescimab-gazyva-becomes-the-first-approved-pmn-therapy-and-a-nanobody-approval-in-myasthenia-gravis</loc>
      <lastmod>2026-11-16T16:42:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:42:31.222Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: FDA Rejects Ivonescimab, Gazyva Becomes the First Approved pMN Therapy, and a Nanobody Approval in Myasthenia Gravis]]></news:title>
      </news:news>
	</url></urlset>